1. APIs
  2. Norethindrone Acetate
  3. Metabolites
  4. Norethindrone
  1. APIs
  2. Norethindrone Enanthate
  4. Norethindrone
  1. APIs
  2. Lynestrenol
  3. Metabolites
  4. Norethindrone
  1. APIs
  2. Norethynodrel
  3. Metabolites
  4. Norethindrone
  1. APIs
  2. Ethynodiol Diacetate
  3. Metabolites
  4. Norethindrone

Norethindrone

Structure

CASRN

68-22-4

Notes

Norethindrone acetate, norethindrone enanthate, lynestrenol, and ethynodiol diacetate (and to a very small extent, norethynodrel) are prodrugs of norethindrone. Conversion of lynestrenol to ethynodiol to norethindrone facilitated by CYP2C9, CYP2C19, and CYP3A4. Conversion of norethynodrel to norethindrone is accomplished by either non-enzymatic or enzymatic ketosteroid isomerization.

References

  1. WHO International Agency for Research on Cancer: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Volume 91: Combined Estrogen-Progestogen Contraceptives and Combined Estrogen-Progestogen Menopausal Therapy. 2007, Lyon, France. (View all citations for this reference)
  2. Jin, Y., Duan, L., Chen, M., Penning, T. M., & Kloosterboer, H. (2012). Metabolism of the synthetic progestogen norethynodrel by human ketosteroid reductases of the aldo-keto reductase superfamily. Journal of Steroid Biochemistry and Molecular Biology, 129(3–5), 139–144. (View all citations for this reference)